ClinicalTrials.gg
CompletedNCT06165146Updated Mar 17, 2025Results posted

A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants

A Phase 1 interventional study of Repaglinide and Pirtobrutinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Nov 2020, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the effect of pirtobrutinib (LOXO-305) on single oral dose of repaglinide (CYP2C8 substrate) when administered as multiple doses by conducting the blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) in adult healthy participants. The study will also evaluate the safety and tolerability of pirtobrutinib (LOXO-305). The study is conducted in two periods. Participants will stay in this study for up to 54 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have (BMI) within the range of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
  • Male and female participants in good health, determined by no findings from medical history, 12-lead (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator
  • Female participants of non- and male participants who follow standard methods
  • Must have comply with all study procedures, including the 16-night stay at the Clinical Research Unit (CRU) and follow-up phone call

Exclusion criteria

Exclusion Criteria:

  • History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor
  • Known ongoing alcohol and/or drug abuse within 2 years prior to Screening
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Period 1: 0.5 mg Repaglinide

    Participants received a single oral dose of 0.5 milligrams (mg) repaglinide tablet, in the morning on Day 1.

    Drug: Repaglinide

  • Experimental
    Period 2: 200 mg Pirtobrutinib QD

    Participants received oral doses of 200 mg pirtobrutinib tablets, once daily (QD) in the morning from Day 2 to Day 11.

    Drug: Pirtobrutinib

  • Experimental
    Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide

    Participants received oral doses of 200 mg pirtobrutinib QD and 0.5 mg repaglinide tablets, in the morning on Day 12.

    Drug: Repaglinide · Drug: Pirtobrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Repaglinide

    PK: AUC(0-t) of repaglinide was reported.

    Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)

  2. PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide

    PK: AUC(0-inf) of repaglinide was reported.

    Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)

  3. PK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide

    PK: AUC-inf (%extrap) of repaglinide was reported.

    Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)

  4. PK: Maximum Observed Concentration (Cmax) of Repaglinide

    PK: Cmax of repaglinide was reported.

    Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)

  5. PK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Repaglinide

    PK: Tmax of repaglinide was reported.

    Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)

  6. PK: Apparent Terminal Elimination Rate Constant (Lambda Z) of Repaglinide

    PK: Lambda Z of repaglinide was reported.

    Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)

  7. PK: Apparent Systemic Clearance (CL/F) of Repaglinide

    PK: CL/F of repaglinide was reported.

    Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)

  8. PK: Apparent Plasma Terminal Elimination Half-life (t½) of Repaglinide

    PK: t½ of repaglinide was reported.

    Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)

  9. PK: Apparent Volume of Distribution (Vz/F) of Repaglinide

    PK: Vz/F of repaglinide was reported.

    Time frame: Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)

  10. PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

    PK: AUC0-t of pirtobrutinib was reported.

    Time frame: Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)

  11. PK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib

    PK: AUCtau of pirtobrutinib was reported.

    Time frame: Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)

  12. PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib

    PK: Cmax of pirtobrutinib was reported.

    Time frame: Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)

  13. PK: Concentration Observed at the End of the Dosing Interval (Ctrough) of Pirtobrutinib

    PK: Ctrough of pirtobrutinib was reported.

    Time frame: Period 2: 24-hour post-dose on Day 12

  14. PK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

    PK: Tmax of pirtobrutinib was reported.

    Time frame: Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)

  15. PK: Apparent Systemic Clearance (CL/F) at Steady State of Pirtobrutinib

    PK: CL/F at steady state of pirtobrutinib was reported.

    Time frame: Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)

07

Results

Posted Mar 17, 2025

Participant flow

Period 1 (Day 1)
Participant flow — Period 1 (Day 1)
MilestonePeriod 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QDPeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
Started1600
Completed1600
Not completed000
Washout Period (11 Days)
Participant flow — Washout Period (11 Days)
MilestonePeriod 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QDPeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
Started1600
Completed1600
Not completed000
Period 2 (Day 2 to 11)
Participant flow — Period 2 (Day 2 to 11)
MilestonePeriod 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QDPeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
Started0160
Completed0160
Not completed000
Period 2 (Day 12)
Participant flow — Period 2 (Day 12)
MilestonePeriod 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QDPeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
Started0016
Completed0016
Not completed000

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Repaglinide

PK: AUC(0-t) of repaglinide was reported.

Time frame:
Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Repaglinide
hour*nanogram per milliliter (h*ng/mL)Period 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Repaglinide9.59 ± 36.922.2 ± 56.1
PrimaryPK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide

PK: AUC(0-inf) of repaglinide was reported.

Time frame:
Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide
h*ng/mLPeriod 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Repaglinide9.79 ± 36.522.5 ± 55.7
PrimaryPK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide

PK: AUC-inf (%extrap) of repaglinide was reported.

Time frame:
Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
Reported as:
Geometric mean · percentage of AUC0-inf extrapolated
PK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide
percentage of AUC0-inf extrapolatedPeriod 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Repaglinide1.94 ± 41.81.10 ± 60.6
PrimaryPK: Maximum Observed Concentration (Cmax) of Repaglinide

PK: Cmax of repaglinide was reported.

Time frame:
Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of Repaglinide
nanogram per milliliter (ng/mL)Period 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Maximum Observed Concentration (Cmax) of Repaglinide6.88 ± 59.313.6 ± 47.4
PrimaryPK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Repaglinide

PK: Tmax of repaglinide was reported.

Time frame:
Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
Reported as:
Median · hour
PK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Repaglinide
hourPeriod 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Repaglinide0.625 (0.333 to 1.00)0.750 (0.500 to 1.00)
PrimaryPK: Apparent Terminal Elimination Rate Constant (Lambda Z) of Repaglinide

PK: Lambda Z of repaglinide was reported.

Time frame:
Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
Reported as:
Number · one per hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (Lambda Z) of Repaglinide
one per hour (1/h)Period 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
Participant 10.1280.152
Participant 20.1300.150
Participant 30.2280.151
Participant 40.08470.157
Participant 50.08090.139
Participant 60.1260.141
Participant 70.1380.247
Participant 80.2190.0995
Participant 90.1830.208
Participant 100.1970.218
Participant 110.1470.118
Participant 120.1390.174
Participant 130.1810.148
Participant 140.1050.170
Participant 150.2210.220
Participant 160.09660.325
PrimaryPK: Apparent Systemic Clearance (CL/F) of Repaglinide

PK: CL/F of repaglinide was reported.

Time frame:
Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
Reported as:
Geometric mean · Liter per hour (L/h)
PK: Apparent Systemic Clearance (CL/F) of Repaglinide
Liter per hour (L/h)Period 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Apparent Systemic Clearance (CL/F) of Repaglinide51.1 ± 36.522.2 ± 55.7
PrimaryPK: Apparent Plasma Terminal Elimination Half-life (t½) of Repaglinide

PK: t½ of repaglinide was reported.

Time frame:
Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
Reported as:
Geometric mean · hour
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Repaglinide
hourPeriod 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Repaglinide4.86 ± 34.64.11 ± 30.0
PrimaryPK: Apparent Volume of Distribution (Vz/F) of Repaglinide

PK: Vz/F of repaglinide was reported.

Time frame:
Period 1, Day 1 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose); Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours post-dose)
Reported as:
Geometric mean · Liter
PK: Apparent Volume of Distribution (Vz/F) of Repaglinide
LiterPeriod 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Apparent Volume of Distribution (Vz/F) of Repaglinide358 ± 39.3131 ± 66.0
PrimaryPK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib

PK: AUC0-t of pirtobrutinib was reported.

Time frame:
Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
h*ng/mLPeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib184000 ± 22.1
PrimaryPK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib

PK: AUCtau of pirtobrutinib was reported.

Time frame:
Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib
h*ng/mLPeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib105000 ± 18.0
PrimaryPK: Maximum Observed Concentration (Cmax) of Pirtobrutinib

PK: Cmax of pirtobrutinib was reported.

Time frame:
Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)
Reported as:
Geometric mean · ng/mL
PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib
ng/mLPeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib7220 ± 15.0
PrimaryPK: Concentration Observed at the End of the Dosing Interval (Ctrough) of Pirtobrutinib

PK: Ctrough of pirtobrutinib was reported.

Time frame:
Period 2: 24-hour post-dose on Day 12
Reported as:
Geometric mean · ng/mL
PK: Concentration Observed at the End of the Dosing Interval (Ctrough) of Pirtobrutinib
ng/mLPeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Concentration Observed at the End of the Dosing Interval (Ctrough) of Pirtobrutinib3050 ± 21.8
PrimaryPK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib

PK: Tmax of pirtobrutinib was reported.

Time frame:
Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)
Reported as:
Median · hour
PK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
hourPeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib1.00 (0.500 to 5.00)
PrimaryPK: Apparent Systemic Clearance (CL/F) at Steady State of Pirtobrutinib

PK: CL/F at steady state of pirtobrutinib was reported.

Time frame:
Period 2, Day 12 (Pre-dose, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 42, 78 and 100 hours post-dose)
Reported as:
Geometric mean · Liter per hour (L/h)
PK: Apparent Systemic Clearance (CL/F) at Steady State of Pirtobrutinib
Liter per hour (L/h)Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PK: Apparent Systemic Clearance (CL/F) at Steady State of Pirtobrutinib1.91 ± 18.0

Adverse events

Collected over Baseline up to 23 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: 0.5 mg Repaglinide0/16 (0%)0/16 (0%)2/16 (12.5%)
Period 2: 200 mg Pirtobrutinib QD0/16 (0%)0/16 (0%)6/16 (37.5%)
Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide0/16 (0%)0/16 (0%)1/16 (6.3%)
Most frequent other events
Most frequent other events
EventPeriod 1: 0.5 mg RepaglinidePeriod 2: 200 mg Pirtobrutinib QDPeriod 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide
PetechiaeSkin and subcutaneous tissue disorders0/164/160/16
Abdominal pain upperGastrointestinal disorders0/161/160/16
ConstipationGastrointestinal disorders0/161/160/16
NauseaGastrointestinal disorders1/160/160/16
Feeling abnormalGeneral disorders0/161/160/16
Back painMusculoskeletal and connective tissue disorders1/160/160/16
Muscle spasmsMusculoskeletal and connective tissue disorders0/161/160/16
AcneSkin and subcutaneous tissue disorders0/160/161/16

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Period 1: 0.5 mg Repaglinide
Mean39.1 ± 9.20
Sex: Female, Male
Sex: Female, Male(Participants)Period 1: 0.5 mg Repaglinide
Female5
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Period 1: 0.5 mg Repaglinide
Hispanic or Latino8
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Period 1: 0.5 mg Repaglinide
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White13
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Period 1: 0.5 mg Repaglinide
United States16
08

Study locations

1 site
  • Covance Clinical Research Unit
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Dec 2020, 1 month.

Results were first posted in Mar 2025, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 11, 2023
StartActual
Nov 10, 2020
Primary completionActual
Dec 30, 2020
CompletionActual
Dec 30, 2020
Results first posted
Mar 17, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06165146
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Dec 11, 2023
Start date
Nov 10, 2020
Primary completion
Dec 30, 2020
Completion
Dec 30, 2020
Results posted
Mar 17, 2025
Last update
Mar 17, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Repaglinide · Pirtobrutinib

Start the discussion